Restricted accessResearch articleFirst published online 2021-05
In Silico Evaluation of Human Cathelicidin LL-37 as a Novel Therapeutic Inhibitor of Panton-Valentine Leukocidin Toxin of Methicillin-Resistant Staphylococcus aureus
Incidence of drug resistance in clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) is attributed to its diverse repertoire of virulence factors. Of these virulence determinants, Panton-Valentine Leukocidin (PVL) has been experimentally validated as a prospective drug target due to its conspicuous and comprehensive role in nosocomial infections. This study encompassed an in silico approach to elucidate the antimicrobial potentiality of human cathelicidin LL-37 against PVL toxin of MRSA. Molecular docking studies of LL-37 and its segments with the PVL toxin subunits LukS and LukF were carried out using PatchDock server and the results were refined using FireDock server. The paramount ligand-receptor combination was selected and analyzed based on diverse parametric attributes and compared with the commercial inhibitors of PVL viz. Andrimid, Beclobrate, Beta-sitosterol, Diathymosulfone, and Probucol to determine the most potent inhibitor among them. Our results elucidated that the interaction of LL-37 with the LukS subunit of PVL toxin (minimum global energy of −61.82 kcal/mol) depicted 34 molecular interactions, while the commercial PVL inhibitors depicted fewer and insubstantial interactions. SWISS-ADME (Absorption, Distribution, Metabolism, and Excretion) and ToxinPred analysis of LL-37 further corroborated its null potency of toxicity in systemic milieu. The results obtained may credit this study as basis for the development of LL-37 as a potential inhibitor against virulent MRSA toxins, thereby exalting the treatment regimes for nosocomial infections in health care facilities worldwide.
Get full access to this article
View all access options for this article.
References
1.
NazirA., and KadriS.M.. 2014. An overview of hospital acquired infections and the role of the microbiology laboratory. Int. J. Res. Med. Sci. 2:21–27.
2.
KongC., NeohH., and NathanS.. 2016. Targeting Staphylococcus aureus toxins: a potential form of anti-virulence therapy. Toxins, 8:1–21.
3.
Hildebrandt, J.P. 2015. Pore-forming virulence factors of Staphylococcus aureus destabilize epithelial barriers-effects of alpha-toxin in the early phases of airway infection. AIMS Microbiol. 1:11–36.
4.
European Centre for Disease Prevention and Control. 2015. Antimicrobial resistance surveillance in Europe in 2014. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). ECDC, Stockholm.
5.
FernebroJ.2011. Fighting bacterial infections—future treatment options. Drug Resist. Updat. 14:125–139.
6.
ChukwunonsoE., VeronicaB., ToyoP., ChiagozieE., AmadiC., AbeT., OtohinoyiD.A, OlunuE., and FakoyaA.O.J. 2018. Methicillin-resistant Staphylococcus aureus: a mini review. Int. J. Med. Res. Health Sci. 7:122–127.
7.
DavidM.Z., and DaumR.S.. 2010. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin. Microbiol. Rev. 23:616–687.
8.
JoshiS., RayP., ManchandaV., BajajJ., ChitnisD.S, GautamV., GoswamiP., GuptaV., HarishB.N, KagalA., RaoR., RodriguesC., SardanaR., DeviK.S, SharmaA., and BalajiV.. 2013. Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern. Indian J. Med. Res. 137:363–369.
9.
WatkinsR.R., DavidM.Z, and SalataR.A.. 2012. Current concepts on the virulence mechanisms of methicillin-resistant Staphylococcus aureus. J. Med. Microbiol. 61:1179–1193.
10.
PlataK., RosatoA.E, and WegrzynG.. 2009. Staphylococcus aureus as an infectious agent: overview of biochemistry and molecular genetics of its pathogenicity. Acta Biochim. Pol. 56:597–612.
KaleP., and DhawanB.. 2016. The changing face of community-acquired methicillin-resistant Staphylococcus aureus. Indian J. Med. Microbiol. 34:275–285.
13.
Lakshmi, G.J. 2014. Mechanism of resistance, phenotyping and genotyping of methicillin-resistant Staphylococcus aureus: a review. Int. J. Curr. Microbiol. App. Sci. 4:810–818.
14.
StefanakiC., IeronymakiA., MatoulaT., CaroniC., PolythodorakiE., ChryssouS.E, KontochristopoulosG., and AntoniouC.. 2017. Six-year retrospective review of hospital data on antimicrobial resistance profile of Staphylococcus aureus isolated from skin infections from a single institution in Greece. Antibiotics, 6:1–8.
15.
BoakesE., KearnsA.M, GannerM., PerryC., HillR.L, and EllingtonM.J.. 2011. Distinct bacteriophages encoding Panton-Valentine leukocidin (PVL) among international methicillin-resistant Staphylococcus aureus clones harbouring PVL. J. Clin. Microbiol. 49:684–692.
16.
OtterJ.A., KearnsA.M, FrenchG.L, and EllingtonM.J.. 2010. Panton-Valentine leukocidin-encoding bacteriophage and gene sequence variation in community-associated Methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 16:68–73.
17.
ShallcrossL.J., WilliamsK., HopkinsS., AldridgeR.W, JohnsonA.M, and HaywardA.C.. 2010. Panton-Valentine leukocidin associated staphylococcal disease: a cross-sectional study at a London hospital, England. Clin. Microbiol. Infect. 16:1644–1648.
18.
RaoG.G., BaturaR., NichollR., CooganF., PatelB., BassettP., and KearnsA.M.. 2019. Outbreak report of investigation and control of an outbreak of Panton-Valentine Leukocidin-positive methicillin-sensitive Staphylococcus aureus (PVL-MSSA) infection in neonates and mothers. BMC Infect. Dis. 19:1–7.
19.
NiemannS., BertlingA., BroddeM.F, FenderA.C, Van de VyverH., HussainM., HolzingerD., ReinhardtD., PetersG., HeilmannC., LofflerB., and KehrelB.E.. 2018. Panton-Valentine Leukocidin associated with S. aureus osteomyelitis activates platelets via neutrophil secretion products. Sci. Rep. 8:1–15.
20.
KarliA, YanikK., PaksuM.S, SensoyG., AykanatA., N. YenerN, BeletN., and CeyhanM.. 2016. Disseminated Panton-Valentine leukocidin-positive Staphylococcus aureus infection in a child. Arch. Argent. Pediatr. 114:e75–e77.
21.
AlonzoF., III, and TorresV.J.. 2013. The bicomponent pore-forming leucocidins of Staphylococcus aureus. Microbiol. Mol. Biol. Rev. 78:199–230.
22.
JoubertO., VoegelinJ., GuilletV., TranierS., WernerS., ColinD.A, SerraM.D, KellerD., MonteilH., MoureyL., and PrevostG.. 2007. Distinction between pore assembly by staphylococcal α-toxin versus leukotoxins. J. Biomed. Biotechnol. 2007:25935.
23.
SeilM., NagantC., DehayeJ.P, VandenbrandenM., and LensinkM.F.. 2010. Spotlight on human LL-37, an immunomodulatory peptide with promising cell-penetrating properties. Pharmaceuticals, 3:3435–3460.
24.
YangB.D., ChenQ., SchmidtA.P, AndersonG.M, WangJ.M, WootersJ., OppenheimJ.J, and ChertovO.. 2000. LL-37, the neutrophil granule– and epithelial cell–derived cathelicidin, utilizes formyl peptide receptor–like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 192:1069–1074.
25.
RamosR., DominguesL., and GamaM.. 2011. LL37, a human antimicrobial peptide with immunomodulatory properties. Sci. Against Microb. Pathogens, 2:915–925.
26.
VandammeD., LanduytB., LuytenW., and SchoofsL.. 2012. A comprehensive summary of LL-37, the factotum human cathelicidin peptide. J. Cell. Immunol. 280:22–35.
27.
BermanH.M., WestbrookJ., FengZ., GillilandG., BhatT.N, WeissigH., ShindyalovI.N, and BourneP.E.. 2000. The protein data bank. Nucleic Acids Res. 28:235–242.
28.
Dassault Systèmes BIOVIA. 2016. Discovery studio, v. 16.1.0.15350. Dassault Systèmes, San Diego, CA.
DuhovnyD., NussinovR., and WolfsonH.J.. 2002. Efficient unbound docking of rigid molecules. In R. Guigó and D. Gusfield (eds.), Educational Proceedings of the 2nd Workshop on Algorithms in Bioinformatics. WABI, Rome, Italy, Lecture Notes in Computer, Science, pp. 185–200.
31.
Schneidman-DuhovnyD., InbarY., NussinovR., and WolfsonH.J.. 2005. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res. 33:363–367.
32.
MashiachE., Schneidman-DuhovnyD., AndrusierN., NussinovR., and WolfsonH.J.. 2008. FireDock: a web server for fast interaction refinement in molecular docking. Nucleic Acids Res. 36:W229–W232.
33.
VermaJ.S., GuptaY., NairD., ManzoorN., RautelaR.S, RaiA., and KatochV.M.. 2014. Evaluation of gidB alterations responsible for streptomycin resistance in Mycobacterium tuberculosis. J. Antimicrob. Chemother. 69:2935–2941.
34.
The PyMolecular Graphics systemMOL, version 1.7.4.5. Schrodinger, LLC. Available at http://www.pymol.org (accessed October2, 2020).
35.
YangJ., RoyA., and ZhangY.. 2013. Protein–ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. Bioinformatics, 29:2588–2595.
36.
LaskowskiR.A., and SwindellsM.B.. 2011. LigPlot+: multiple ligand–protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51:2778–2786.
37.
DianaA., MichielinO., and ZoeteV.. 2017. SWISS-ADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 7:1–13.
38.
AliA., El BadawyM., ShahR., RehmanW., El KilanyY., El AshryE.S.H, and TahirN.. 2017. Synthesis, characterization and In-Silico ADMET screening of mono- and dicarbmethoxylated 6,6'-Methylenebis(2-cyclohexyl-4-methylphenol) and their hydrazides and hydrazones. Der Chem. Sin. 8:446–460.
39.
BhaskarB.V., MuniT., ReddyN.V, and RajendraW.. 2016. Homology modeling, molecular dynamics, and virtual screening of NorA efflux pump inhibitors of Staphylococcus aureus. Drug Des. Dev. Ther. 10:3237–3252.
40.
GuptaS., KapoorP., ChaudharyK., GautamA., Kumar and R., RaghavaG.P.S. 2013. In silico approach for predicting toxicity of peptides and proteins. PLoS One, 8:e73957.
41.
LiuX., FortinP.D, and WalshC.T.. 2008. Andrimid producers encode an acetyl Co-A carboxyltransferase subunit resistant to the action of the antibiotic. Proc. Natl. Acad. Sci. U. S. A. 105:13321–13326.
42.
MassyZ.A., MaJ.Z, LouisT.A, and KasiskeB.L.. 1995. Lipid-lowering therapy in patients with real diseases. Kidney Int. 48:188–198.
43.
SayeedM.S.B., KarimS.M.R, SharminT., and MorshedM.M.. 2016. Critical analysis on characterization, systemic effect and therapeutic potential of beta-sitosterol: a plant-derived orphan phytosterol. Medicines, 3:1–25.
44.
NidhinaN., ManibharathiP., NilavazhaganA., SwethaM.P, and MuthukumarS.P.. 2012. In silico molecular modelling and docking studies on leukocidin LUKD in Staphylococcus aureus. J. Biotechnol. Biomater. 2:1–23.
45.
LipinskiC.A., LombardoF., DominyB.W, and FeeneyP.J.. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3–26.
46.
GhoseA.K., ViswanadhanV.N, and WendoloskiJ.J. 1999. knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discoveryA. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1:55–68.
47.
VeberD.F., JohnsonS.R, ChengH.Y, SmithB.R, WardK.W, and KoppleK.D.. 2002. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45:2615–2623.
48.
EganW.J., MerzK.M, and BaldwinJ.J.. 2000. Prediction of drug absorption using multivariate statistics. J. Med. Chem. 43:3867–3877.
49.
MueggeI., HealdS.L, and BrittelliD.. 2001. Simple selection criteria for drug-like chemical matter. J. Med. Chem. 44:1841–1846.
50.
KuokC.F., HoiS.O, HoiC.F, ChanC.H, FongI.H, NgokC.K, MengL.R, and FongP.. 2017. Synergistic antibacterial effects of herbal extracts and antibiotics on methicillin-resistant Staphylococcus aureus: a computational and experimental study. Exp. Biol. Med. 242:731–743.
51.
SkariyachanS., KrishnanR.S, SiddapaS.B, SalianC., BoraP., and SebastianD.. 2011. Computer aided screening and evaluation of herbal therapeutics against MRSA infections. Bioinformation, 7:222–233.
52.
UsaiD., DonaduM., BuaA., MolicottiP., ZanettiS., PirasS., CoronaP., IbbaR., and CartaA.. 2019. Enhancement of antimicrobial activity of pump inhibitors associating drugs. J. Infect. Dev. Ctries. 13:162–164.
53.
MazzarelloV., GavaniE., RassuG., DonaduM.G, UsaiD., PiuG., PomponiV., SucatoF., ZanettiS., and MontesuM.A.. 2020. Clinical assessment of new topical cream containing two essential oils combined with tretinoin in the treatment of acne. Clin. Cosmet. Investig. Dermatol. 13:233–239.
54.
Chavez-LopezC., UsaiD., DonaduM.G, SerioA., Gonzalez-MinaR.T, SimeoniM.C, MolicottiP., ZanettiS., PinnaA., and PaparellaA.. 2018. Potential of Borojoa patinoi Cuatrecasas water extract to inhibit nosocomial antibiotic resistant bacteria and cancer cell proliferation in vitro. Food Funct. 9:2725–2734.
55.
BanerjeeD., GohilT., PatelR., and ShahK.. 2015. Catechol and Eugenol reversing the resistance of MRSA towards the β-lactam antibiotics. Asian J. Microbiol. Biotechnol. Environ. Sci. 17:139–144.
56.
KaliA. Antibiotics and bioactive natural products in treatment of Methicillin resistant Staphylococcus aureus: a brief review. Pharmocogn. Rev. 9:29–34.
57.
PfalzgraffA., BrandenburgK., and WeindlG.. 2018. Antimicrobial peptides and their therapeutic potential for bacterial skin infections and wounds. Front. Pharmacol. 9:1–23.
58.
JooH.S., and OttoM.. 2015. Mechanisms of resistance to antimicrobial peptides in Staphylococci. Biochim. Biophys. Acta, 1848:3055–3061.
59.
BotoA., de la LastraJ.M.P, and GonzálezC.C.. 2018. The road from host-defense peptides to a new generation of antimicrobial drugs. Molecules, 23:1–26.
60.
NagarajanD., NagarajanT., RoyN., KulkarniO., RavichandranS., MishraM., ChakravorttyD., and ChandraN.. 2018. Computational antimicrobial peptide design and evaluation against multidrug-resistant clinical isolates of bacteria. J. Biol. Chem. 293:3492–3509.
61.
MengX., ZhangH., MezeiM., and CuiM.. 2011. Molecular docking: a powerful approach for structure-based drug discovery. Curr. Comput. Aided Drug Des. 7:146–157.
62.
CortesE., MoraJ., and MarquezE.. 2020. Modelling the anti- methicillin-resistant Staphylococcus aureus (MRSA) activity of cannabinoids: a QSAR and docking study. Crystals, 10:1–20.
63.
Fitzgerald-HughesD., DevocelleM., and HumphreysH.. 2012. Beyond conventional antibiotics for the future treatment of methicillin-resistant Staphylococcus aureus infections: two novel alternatives. FEMS Immunol. Med. Microbiol. 65:399–412.
64.
HaismamE.M., de BreijA., ChanH., van DisselJ.T, DrijfhoutJ.W, HiemstraP.S, El GhalbzouriA., and NibberingP.H.. 2014. LL-37-derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents. Antimicrob. Agents Chemother. 58:4411–4419.
65.
MingL., and HuangJ.A.. 2017. The antibacterial effects of antimicrobial peptides OP-145 against clinically isolated multi-resistant strains. Jpn. J. Infect. Dis. 70:601–603.
66.
RenX.S., ShenJ., ChengA.S.L, LuL., ChanR.L.Y, LiZ.J, WangX.J, WongC.C.M, ZhangL., NgS.S.M, ChanF.L, ChanF.K.L, YuJ., SungJ.J.Y, WuW.K.K, and ChoC.H.. 2013. FK-16 derived from the anticancer peptide LL-37 induces caspase-independent apoptosis and autophagic cell death in colon cancer cells. PLoS One, 8:1–9.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
